Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer
Participating Faculty
Recognizing and Addressing Challenges to the Adoption of Trastuzumab Biosimilars and HER2-Targeted Therapies
Integrating Trastuzumab Biosimilars and HER2-Directed Therapies into HER2-Positive Breast Cancer Management